[生存素、乳腺癌耐药蛋白及人表皮生长因子受体2基因表达与TE方案新辅助化疗治疗乳腺癌患者疗效的相关性]

[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].

作者信息

Li Xun, Li Yan, Yang Shun-e, Ma Ying, Wen Shu-juan, Guo Li, Guli Ke-zi, Zhao Bing, Liu Wei, Hu Xin

机构信息

Department of Chemotherapy, Affiliated Tumor Hospital of Medical University, Urumqi 830011, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):916-20.

PMID:22340101

Abstract

OBJECTIVE

To study the changes of expression of Survivin mRNA, BCRP mRNA and HER-2 mRNA in breast cancer after TE regimen neoadjuvant chemotherapy, and to find biological markers to predict the efficiency of TE regimen neoadjuvant chemotherapy.

METHODS

The gene expressions were detected by RT-PCR from 56 breast cancer patients before and after TE regimen neoadjuvant chemotherapy (docetaxel and epirubicin). The relationships between these gene expressions and chemotherapy responses were analyzed.

RESULTS

The overall response rate to neoadjuvant chemotherapy was 71.4%, including 8.9% (5/56) with complete response and 62.5% (35/56) with partial response. Pathological complete response was found in 4 cases (7.1%). Stable disease and progression of disease were 23.2% (13/56) and 5.4% (3/56), respectively. The expression of Survivin mRNA after neoadjuvant chemotherapy was 35.7% (20/56), significantly lower than 60.7% (34/56) before neoadjuvant chemotherapy (P = 0.008). The expression of BCRP mRNA after neoadjuvant chemotherapy was 19.6%, significantly lower than 37.5% before neoadjuvant chemotherapy (P = 0.036). The positive rate of HER-2 mRNA expression was 41.1% before the chemotherapy, and reduced to 21.4% after the chemotherapy (P = 0.025). The effective rates of the single positive expression of Survivin mRNA or BCRP mRNA were both lower than that of negative expression (P < 0.05). The level of HER-2 mRNA expression alone was not significantly associated with the effective rate of chemotherapy (P = 0.144). When the expression of all Survivin mRNA, BCRP mRNA and HER-2 mRNA were negative, the effective rate of neoadjuvant chemotherapy was higher than that in patients with positive expression (P = 0.003). The level of Survivin mRNA expression was not significantly associated with BCRP mRNA and HER-2 mRNA (P > 0.05).

CONCLUSION

The expression of Survivin in combination with BCRP and HER-2 is associated with clinical response to TE neoadjuvant chemotherapy in breast cancer, and can be used as predictive biomarkers for chemosensitivity of TE regimen neoadjuvant chemotherapy for breast cancer.

摘要

目的

研究TE方案（多西他赛联合表柔比星）新辅助化疗后乳腺癌组织中Survivin mRNA、BCRP mRNA及HER-2 mRNA表达变化，寻找预测TE方案新辅助化疗疗效的生物学标志物。

方法

采用RT-PCR法检测56例乳腺癌患者TE方案新辅助化疗前后上述基因表达情况，并分析其与化疗疗效的关系。

结果

新辅助化疗总有效率为71.4%，其中完全缓解8.9%（5/56），部分缓解62.5%（35/56），病理完全缓解4例（7.1%），疾病稳定和疾病进展分别为23.2%（13/56）和5.4%（3/56）。新辅助化疗后Survivin mRNA表达率为35.7%（20/56），显著低于新辅助化疗前的60.7%（34/56）（P = 0.008）。新辅助化疗后BCRP mRNA表达率为19.6%，显著低于新辅助化疗前的37.5%（P = 0.036）。化疗前HER-2 mRNA阳性率为41.1%，化疗后降至21.4%（P = 0.025）。Survivin mRNA或BCRP mRNA单阳性表达的有效率均低于阴性表达（P < 0.05）。单独HER-2 mRNA表达水平与化疗有效率无明显相关性（P = 0.144）。当Survivin mRNA、BCRP mRNA及HER-2 mRNA表达均为阴性时，新辅助化疗有效率高于阳性表达患者（P = 0.003）。Survivin mRNA表达水平与BCRP mRNA及HER-2 mRNA无明显相关性（P > 0.05）。